share_log

復星醫藥：海外監管公告-中國國際金融股份有限公司關於上海復星醫藥（集團）股份有限公司2023年度持續督導年度報告書

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 17:52
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年4月2日發布海外監管公告，公佈了由中國國際金融股份有限公司（簡稱「中金公司」）出具的2023年度持續督導年度報告書。報告書顯示，復星醫藥在2023年度未發生任何違法違規或違背承諾等事項，並且公司及其董事、監事、高級管理人員均遵守相關法律法規，切實履行了各項承諾。中金公司作為保薦機構，確認復星醫藥的信息披露真實、準確、完整、及時且有效，並無虛假記載、誤導性陳述或重大遺漏。此外，安永華明會計師事務所對復星醫藥2023年度的財務報告內部控制的有效性進行了審計，並出具了標準無保留意見的審計報告。復星醫藥此前非公開發行了106,756,666股境內上市普通股（A股），募集資金總額為人民幣448,378.00萬元，扣除發行費用後的募集資金淨額為445,619.87萬元。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年4月2日發布海外監管公告，公佈了由中國國際金融股份有限公司（簡稱「中金公司」）出具的2023年度持續督導年度報告書。報告書顯示，復星醫藥在2023年度未發生任何違法違規或違背承諾等事項，並且公司及其董事、監事、高級管理人員均遵守相關法律法規，切實履行了各項承諾。中金公司作為保薦機構，確認復星醫藥的信息披露真實、準確、完整、及時且有效，並無虛假記載、誤導性陳述或重大遺漏。此外，安永華明會計師事務所對復星醫藥2023年度的財務報告內部控制的有效性進行了審計，並出具了標準無保留意見的審計報告。復星醫藥此前非公開發行了106,756,666股境內上市普通股（A股），募集資金總額為人民幣448,378.00萬元，扣除發行費用後的募集資金淨額為445,619.87萬元。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED AN OVERSEAS REGULATORY NOTICE ON APRIL 2, 2024 AND ANNOUNCED THE 2023 ANNUAL SUPERVISORY REPORT ISSUED BY CHINA INTERNATIONAL FINANCIAL CORPORATION (“CHINA GOLD CORPORATION”). The report shows that there were no breaches of law or breach of commitments in 2023, and that the company and its directors, supervisors and senior managers complied with the relevant laws and regulations and fulfilled their commitments. AS A SPONSORSHIP AGENCY, CENTRAL CORPORATION ENSURES THAT THE DISCLOSURE OF INFORMATION ABOUT STAR PHARMACEUTICALS IS TRUE, ACCURATE, COMPLETE, TIMELY AND EFFECTIVE WITHOUT FALSE RECORDS, MISLEADING STATEMENTS OR MATERIAL OMISSIONS. In addition, EY's accounting firm audited the effectiveness of internal controls on the financial statements of Panasonic Pharmaceuticals 2023 and issued standard unreserved audit reports. FUSTAR PHARMACEUTICALS HAS PREVIOUSLY NON-PUBLICLY ISSUED 106,756,666 DOMESTIC LISTED ORDINARY SHARES (A SHARES) FOR A TOTAL RAISING OF RMB448,378.00 MILLION AND NET RAISING FUNDS AFTER ISSUANCE FEES OF RMB445,619.87 MILLION.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED AN OVERSEAS REGULATORY NOTICE ON APRIL 2, 2024 AND ANNOUNCED THE 2023 ANNUAL SUPERVISORY REPORT ISSUED BY CHINA INTERNATIONAL FINANCIAL CORPORATION (“CHINA GOLD CORPORATION”). The report shows that there were no breaches of law or breach of commitments in 2023, and that the company and its directors, supervisors and senior managers complied with the relevant laws and regulations and fulfilled their commitments. AS A SPONSORSHIP AGENCY, CENTRAL CORPORATION ENSURES THAT THE DISCLOSURE OF INFORMATION ABOUT STAR PHARMACEUTICALS IS TRUE, ACCURATE, COMPLETE, TIMELY AND EFFECTIVE WITHOUT FALSE RECORDS, MISLEADING STATEMENTS OR MATERIAL OMISSIONS. In addition, EY's accounting firm audited the effectiveness of internal controls on the financial statements of Panasonic Pharmaceuticals 2023 and issued standard unreserved audit reports. FUSTAR PHARMACEUTICALS HAS PREVIOUSLY NON-PUBLICLY ISSUED 106,756,666 DOMESTIC LISTED ORDINARY SHARES (A SHARES) FOR A TOTAL RAISING OF RMB448,378.00 MILLION AND NET RAISING FUNDS AFTER ISSUANCE FEES OF RMB445,619.87 MILLION.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.